Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with GoutThe New England journal of medicine, 2018-03, Vol.378 (13), p.1200-1210 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1710895 ;PMID: 29527974Full text available |
|
2 |
Material Type: Article
|
Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort StudyCirculation (New York, N.Y.), 2018-09, Vol.138 (11), p.1116-1126 [Peer Reviewed Journal]2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. ;ISSN: 0009-7322 ;EISSN: 1524-4539 ;DOI: 10.1161/CIRCULATIONAHA.118.033992 ;PMID: 29899013Full text available |
|
3 |
Material Type: Article
|
Impact of Febuxostat on Renal Function in Gout Patients With Moderate‐to‐Severe Renal ImpairmentArthritis & rheumatology (Hoboken, N.J.), 2016-08, Vol.68 (8), p.2035-2043 [Peer Reviewed Journal]2016, American College of Rheumatology ;2016, American College of Rheumatology. ;ISSN: 2326-5191 ;EISSN: 2326-5205 ;DOI: 10.1002/art.39654 ;PMID: 26894653Full text available |
|
4 |
Material Type: Article
|
Optimal uric acid levels by febuxostat treatment and cerebral, cardiorenovascular risks: post hoc analysis of a randomized controlled trialRheumatology (Oxford, England), 2022-05, Vol.61 (6), p.2346-2359 [Peer Reviewed Journal]The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021 ;The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 1462-0324 ;EISSN: 1462-0332 ;DOI: 10.1093/rheumatology/keab739 ;PMID: 34605897Full text available |
|
5 |
Material Type: Article
|
Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD studyScientific reports, 2019-04, Vol.9 (1), p.6681-6681, Article 6681 [Peer Reviewed Journal]The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-019-43241-3 ;PMID: 31040373Full text available |
|
6 |
Material Type: Article
|
Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysisRheumatology (Oxford, England), 2017-07, Vol.56 (7), p.1144-1153 [Peer Reviewed Journal]The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com ;ISSN: 1462-0324 ;EISSN: 1462-0332 ;DOI: 10.1093/rheumatology/kex065 ;PMID: 28379501Full text available |
|
7 |
Material Type: Article
|
Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in miceScientific reports, 2020-01, Vol.10 (1), p.815, Article 815 [Peer Reviewed Journal]This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-020-57784-3 ;PMID: 31965018Full text available |
|
8 |
Material Type: Article
|
Comparison of clinical and economic evaluation between selected generic and original febuxostat tablets in Chinese gout patients with hyperuricemia: A real-world multicenter retrospective studyMedicine (Baltimore), 2024-01, Vol.103 (4), p.e37081-e37081 [Peer Reviewed Journal]Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. ;ISSN: 0025-7974 ;EISSN: 1536-5964 ;DOI: 10.1097/MD.0000000000037081 ;PMID: 38277524Full text available |
|
9 |
Material Type: Article
|
Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER StudyScientific reports, 2022-03, Vol.12 (1), p.3784-3784, Article 3784 [Peer Reviewed Journal]2022. The Author(s). ;The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2022 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-022-07737-9 ;PMID: 35260678Full text available |
|
10 |
Material Type: Article
|
Incorporating gout guideline advice into urate reports is associated with reduced hospital admissions: results of an observational studyRheumatology (Oxford, England), 2022-05, Vol.61 (5), p.1885-1891 [Peer Reviewed Journal]The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021 ;The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 1462-0324 ;EISSN: 1462-0332 ;DOI: 10.1093/rheumatology/keab689 ;PMID: 34528071Full text available |
|
11 |
Material Type: Article
|
Trends in healthcare utilization by patients with gout: A cross-sectional study using Health Insurance Review and Assessment Service dataMedicine (Baltimore), 2024-02, Vol.103 (7), p.e36436-e36436 [Peer Reviewed Journal]Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. ;Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc. 2024 ;ISSN: 0025-7974 ;EISSN: 1536-5964 ;DOI: 10.1097/MD.0000000000036436 ;PMID: 38363901Full text available |
|
12 |
Material Type: Article
|
Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort studyRheumatology (Oxford, England), 2019-12, Vol.58 (12), p.2122-2129 [Peer Reviewed Journal]The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2019 ;The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 1462-0324 ;EISSN: 1462-0332 ;DOI: 10.1093/rheumatology/kez189 ;PMID: 31098635Full text available |
|
13 |
Material Type: Article
|
The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patientsArthritis research & therapy, 2019-03, Vol.21 (1), p.77-77, Article 77 [Peer Reviewed Journal]COPYRIGHT 2019 BioMed Central Ltd. ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2019 ;ISSN: 1478-6362 ;ISSN: 1478-6354 ;EISSN: 1478-6362 ;DOI: 10.1186/s13075-019-1860-8 ;PMID: 30894219Full text available |
|
14 |
Material Type: Article
|
Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary goutArthritis research & therapy, 2023-12, Vol.25 (1), p.241-241, Article 241 [Peer Reviewed Journal]2023. The Author(s). ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 1478-6362 ;ISSN: 1478-6354 ;EISSN: 1478-6362 ;DOI: 10.1186/s13075-023-03228-y ;PMID: 38082308Full text available |
|
15 |
Material Type: Article
|
Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trialsAnnals of medicine (Helsinki), 2024-12, Vol.56 (1), p.2332956-2332956 [Peer Reviewed Journal]2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2024 The Author(s) ;ISSN: 0785-3890 ;EISSN: 1365-2060 ;DOI: 10.1080/07853890.2024.2332956 ;PMID: 38738384Full text available |
|
16 |
Material Type: Article
|
Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis InfectionAntimicrobial agents and chemotherapy, 2022-09, Vol.66 (9), p.e0076222 [Peer Reviewed Journal]Copyright © 2022 American Society for Microbiology. ;Copyright © 2022 American Society for Microbiology. 2022 American Society for Microbiology ;ISSN: 0066-4804 ;EISSN: 1098-6596 ;DOI: 10.1128/aac.00762-22 ;PMID: 36040172Full text available |
|
17 |
Material Type: Article
|
Differential effect of a xanthine oxidase inhibitor on arterial stiffness and carotid atherosclerosis: a subanalysis of the PRIZE studyHypertension research, 2022-04, Vol.45 (4), p.602-611 [Peer Reviewed Journal]2022. The Author(s), under exclusive licence to The Japanese Society of Hypertension. ;The Author(s), under exclusive licence to The Japanese Society of Hypertension 2022. ;ISSN: 0916-9636 ;EISSN: 1348-4214 ;DOI: 10.1038/s41440-022-00857-9 ;PMID: 35169280Full text available |
|
18 |
Material Type: Article
|
Clinical characteristics of juvenile gout and treatment response to febuxostatAnnals of the rheumatic diseases, 2022-04, Vol.81 (4), p.599-600 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-221762 ;PMID: 34930759Full text available |
|
19 |
Material Type: Article
|
Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant articleMedicine (Baltimore), 2018-03, Vol.97 (13), p.e0161-e0161 [Peer Reviewed Journal]Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. 2018 ;ISSN: 0025-7974 ;EISSN: 1536-5964 ;DOI: 10.1097/MD.0000000000010161 ;PMID: 29595642Full text available |
|
20 |
Material Type: Article
|
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based UpdateMedicina (Kaunas, Lithuania), 2021-01, Vol.57 (1), p.58 [Peer Reviewed Journal]2021 by the authors. 2021 ;ISSN: 1648-9144 ;ISSN: 1010-660X ;EISSN: 1648-9144 ;DOI: 10.3390/medicina57010058 ;PMID: 33435164Full text available |